Keol-C

Oxygen, the active ingredient in Keol-C, is a medical gas presented as a medical gas for inhalation use. It is employed to treat hypoxemia, respiratory distress, carbon monoxide poisoning, and to support anesthesia by increasing arterial oxygen tension and improving tissue oxygenation. GNH USA supplies Keol-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Keol-C provides supplemental oxygen for conditions affecting the respiratory system and oxygen delivery. - Hypoxemia: raises arterial oxygen levels to correct low blood oxygen. - Respiratory distress: supports breathing in acute or chronic respiratory failure. - Carbon monoxide poisoning: displaces carbon monoxide from hemoglobin and restores oxygen transport. - Anesthesia support: maintains adequate oxygenation during surgical procedures.

Oxygen therapy may be associated with both common and serious adverse reactions.

Common Side Effects: - Nasal dryness or irritation - Throat discomfort - Headache - Fatigue - Cough - Mild dizziness

Serious or Rare Side Effects: - Fire hazard when used near open flames - Oxygen toxicity causing lung injury - Pulmonary edema in susceptible patients - Seizures due to high oxygen concentrations - Visual disturbances from retinal oxygen overload

When using Keol-C, several safety considerations should be observed. - Assess patient oxygen saturation before and during therapy: monitor with pulse oximetry. - Adjust flow rates according to clinical response: avoid excessive concentrations. - Avoid use in patients with known hypercapnia without monitoring: risk of CO₂ retention. - Keep away from ignition sources: oxygen supports combustion. - Store at ambient temperature: keep cylinders upright, protect from heat and direct sunlight.

Oxygen can interact with certain agents and conditions, requiring careful management.

Major Interactions (Avoid): - Flammable anesthetic gases (e.g., nitrous oxide) in high concentrations. - Smoking or open flames in the treatment area. - Certain pulmonary drugs that increase oxygen sensitivity (e.g., bleomycin). - High‑concentration oxygen with patients having chronic obstructive pulmonary disease (risk of CO₂ retention).

Moderate Interactions (Monitor Closely): - Bronchodilators that may alter oxygen demand. - Corticosteroids that can affect lung tissue response. - Sedatives that depress respiratory drive. - Antioxidant therapies that may modify oxidative stress balance.